Key result
In patients with moderate COPD, 3 months of indacaterol therapy significantly improved right ventricular contractility, increasing TAPSE from 18.57 mm at baseline to 22.10 mm.
Why the study?
Does indacaterol 150 mg daily improve cardiovascular parameters in patients with moderate to severe COPD?
Observational (n=25)
Open-label
No
Does indacaterol 150 mg daily improve cardiovascular parameters in patients with moderate to severe COPD?
Absolute Event Rate: 22.1% vs 18.57%
p-value: p=0.0004
In patients with COPD, 3 months of indacaterol therapy improved right ventricular contractility (TAPSE) and autonomic function, particularly in highly compliant patients.
Indacaterol was associated with improved RV contractility in moderate COPD; hypothesis-generating and requires randomized confirmation before practice change.
The aim of this study was to investigate cardiovascular effects of the inhaled betaagonist indacaterol in COPD patients. Methods. In this prospective reallife nonrandomized study, 25 patients with moderate COPD were treated with indacaterol for 3 months. Lung function testing, echocardiography, measurements of arterial stiffness, pulse wave velocity, heart rate variability and compliance were done. Results. Tendencies to the heart size reduction, decrease in the pulmonary artery pressure, improvement in the heart contractility and autonomous functions were seen after 3 months of the therapy. The lung function parameters did not change reliably. These changes were more significant in compliant patients (18 of 25). Conclusions. Therapy of COPD patients with indacaterol 150 mg daily improved the cardiovascular status.
No takes yet. Share an insight, caveat, or question.
Загидуллин et al. (2016) conducted an observational in Chronic Obstructive Pulmonary Disease (COPD) (n=25). Indacaterol vs. Baseline (no control group) was evaluated on Tricuspid Annulus Plane Systolic Excursion (TAPSE) (p=0.0004). In patients with moderate COPD, 3 months of indacaterol therapy significantly improved right ventricular contractility, increasing TAPSE from 18.57 mm at baseline to 22.10 mm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: